West Pharmaceutical stock: 2026 outlook rises after Q3 growth

Published on 11/03/2026 at 13:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

West Pharmaceutical stock gained a stronger outlook after improved third-quarter results. Revenue and adjusted earnings guidance both moved higher.

Outlook rises after stronger quarter

West Pharmaceutical Services lifted its full-year revenue and adjusted earnings outlook after third-quarter growth.
Higher sales and earnings strengthen the company case, while execution and demand remain key investor focus areas.

West Pharmaceutical, US9553061055, Illustration mit AI erstellt.

West Pharmaceutical Services raised its full-year outlook after reporting stronger third-quarter results, according to RTTNews. The announcement was published on Thursday, October 29, 2026.

For full-year 2026, management now expects revenue of USD 3.41 billion to USD 3.42 billion, compared with its previous range of USD 3.345 billion to USD 3.380 billion. Adjusted earnings per share guidance increased to USD 9.38 to USD 9.48 from USD 8.85 to USD 9.05.

Third-quarter growth supports guidance

Third-quarter net income rose to USD 214.0 million, or USD 3.02 per share, from USD 140.0 million, or USD 1.92 per share, a year earlier. Adjusted earnings reached USD 2.66 per share, while revenue increased 8.7 percent to USD 874.5 million from USD 804.6 million.

The figures give investors a stronger operating reference for the remainder of the year. The higher forecast also raises the importance of maintaining demand and execution across West Pharmaceutical Services' packaging and delivery systems for injectable drugs.

West Pharmaceutical stock traded at 362.50 euros on Lang & Schwarz at 13:37 CET on Tuesday, November 3, 2026. Investors can monitor the real-time quote of West Pharmaceutical stock.